Obalon Therapeutics, Inc. (NASDAQ:OBLN) tinted gains of +1.17% (+0.02 points) to US$1.73. The volume of 0.06 Million shares climbed down over an trading activity of 280.47 Million shares. EPS ratio determined by looking at last 12 month figures is -2.02. Over the same time span, the stock marked US$4.41 as its best level and the lowest price reached was US$1.46. The corporation has a market cap of US$40.64 Million.
Obalon Therapeutics, Inc. (NASDAQ:OBLN)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -202.8 percent while most common profitability ratio return on investment (ROI) was -160.7 percent. The company’s institutional ownership is monitored at 56.4 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 40.4 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 1.83. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Helix Energy Solutions Group, Inc. (NYSE:HLX) is worth US$1.18 Billion and has recently risen 1.16% to US$7.83. The latest exchange of 1.08 Million shares is below its average trading activity of 1.28 Million shares. The day began at US$7.79 but the price moved to US$7.76 at one point during the trading and finally capitulating to a session high of US$7.93. The stock tapped a 52-week high of US$10.89 while the mean 12-month price target for the shares is US$10.1.
Currently, the stock carries a price to earnings ratio of 40.57, a price to book ratio of 0.71, and a price to sales ratio of 1.6. For the past 5 years, the company’s revenue has grown -3.3%, while the company’s earnings per share has grown -28.4%. With an institutional ownership near 99.3%, it carries an earnings per share ratio of 0.19.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 5 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.83.